Postmarketing Safety Concerns With FDA Black Box Warning Monoclonal Antibodies: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database
- DOI
- 10.1097/pts.0000000000001513
- Published
- 2026-05-11
- Container
- Journal of Patient Safety
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1097/pts.0000000000001513,
title = {Postmarketing Safety Concerns With FDA Black Box Warning Monoclonal Antibodies: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database},
author = {K. Kalaivani and S. Chandrasekaran and S.D. Rajendran and V. Munishwararaj and T.M. Vijayakumar},
year = {2026},
journal = {Journal of Patient Safety},
doi = {10.1097/pts.0000000000001513},
url = {https://doi.org/10.1097/pts.0000000000001513}
}RIS
TY - JOUR TI - Postmarketing Safety Concerns With FDA Black Box Warning Monoclonal Antibodies: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database AU - K. Kalaivani AU - S. Chandrasekaran AU - S.D. Rajendran AU - V. Munishwararaj AU - T.M. Vijayakumar PY - 2026 JO - Journal of Patient Safety DO - 10.1097/pts.0000000000001513 UR - https://doi.org/10.1097/pts.0000000000001513 ER -
APA
Kalaivani, K., Chandrasekaran, S., Rajendran, S., Munishwararaj, V., & Vijayakumar, T. (2026). Postmarketing Safety Concerns With FDA Black Box Warning Monoclonal Antibodies: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database. Journal of Patient Safety. https://doi.org/10.1097/pts.0000000000001513
Source records
- crossref · retrieved 2026-11-10T20:01:47.099Z